Article

B + L acquires technology to treat ocular redness

Bausch + Lomb (B + L) has acquired an exclusive global license to a technology that may lead to a faster, more effective, and longer-lasting treatment for ocular redness.

 

Madison, NJ-Bausch + Lomb (B + L) has acquired an exclusive global license to a new-platform technology that may lead to a faster, more effective, and longer-lasting treatment for ocular redness.

The technology uses a uniquely formulated low dose of brimonidine to relieve ocular redness, a different mechanism of action from currently available products. The technology is licensed from Eye Therapies, LLC, a privately held biopharmaceutical company, and was developed in collaboration with Ora Inc., a private research organization.

“Ocular redness is associated with reduced quality of life and negative social connotations, and may [affect] compliance with certain medications,” explained Dr. Cal Roberts, chief medical officer, Bausch + Lomb. “The decision to license this promising new technology underscores our continued commitment to delivering solutions for physicians and their patients.”

“We are proud to be working with Bausch + Lomb to develop this promising new technology,” said Lee Nordan, MD, chief executive officer of Eye Therapies, LLC. “The company’s commitment, expertise, and resources, combined with its global reach, will help ensure that, if approved, this technology will reach its full potential.”

For more articles in this issue of Ophthalmology Times eReport,click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Dr. Wendy Lee at Controversies in Modern Eyecare 2025
I. Paul Singh, MD, speaks about glaucoma treatment and successful ophthalmic / optometric comanagement at the 19th Annual Controversies in Modern Eye Care meeting
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
© 2025 MJH Life Sciences

All rights reserved.